19 episodes

In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.
The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.
Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.

Oncology Times Broadcast News Oncolgy Times & Audio Medica

    • Science

In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.
The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.
Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.

    Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

    Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

    Oncology Times Broadcast News

    Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

    Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.

    • 4 min
    Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

    Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

    Oncology Times Broadcast News

    Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

    Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

    • 6 min
    Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

    Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

    John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.

    • 7 min
    For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

    For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

    Oncology Times Broadcast News

    For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

    Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.

    • 6 min
    Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer

    Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer

    Oncology Times Broadcast News:

    Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer

    For adjuvant treatment of stage II and stage III colorectal cancer the vascular endothelial growth factor (VEGF) receptor inhibitor, bevacizumab, gave no benefit in disease-free survival after a median follow up of three years when added to standard oxaliplatin-based chemotherapy in the NSABP C-O8 phase III study reported at the 2009 ASCO meeting held in Orlando, Florida .
    Lead author Dr Norman Wolmark MD Chair of the National Surgical Adjuvant Breast and Bowel Project, and Chair of the Department of Oncology at Allegheny General Hospital in Pittsburgh, said in an interview with Peter Goodwin: "These data do not support using bevacizumab in the adjuvant setting."

    • 9 min
    "Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer

    "Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer

    BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1.
    She discussed her team’s findings with Peter Goodwin.

    • 2 min

Top Podcasts In Science

Listeners Also Subscribed To